Cargando…
Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials
INTRODUCTION: This review aims to assess the efficacy, durability and safety of faricimab—a dual vascular endothelial growth factor and angiopoietin 2 inhibitor—in patients with neovascular age-related macular degeneration (nAMD) and diabetic macula oedema (DMO). It summarises the findings of curren...
Autores principales: | Larsen, Helene O., Grauslund, Jakob, Vergmann, Anna S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441964/ https://www.ncbi.nlm.nih.gov/pubmed/37410309 http://dx.doi.org/10.1007/s40123-023-00753-6 |
Ejemplares similares
-
Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
por: Ferro Desideri, Lorenzo, et al.
Publicado: (2023) -
Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
por: Rush, Ryan B, et al.
Publicado: (2022) -
Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review
por: Liberski, Sławomir, et al.
Publicado: (2022) -
The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 month results
por: Khanani, Arshad M., et al.
Publicado: (2023) -
Machine Learning to Predict Faricimab Treatment Outcome in Neovascular Age-Related Macular Degeneration
por: Kikuchi, Yusuke, et al.
Publicado: (2023)